For Small Cell Lung Cancer, Rechallenge Chemotherapy Not Superior to Other Regimens

Share this content:

the Cancer Therapy Advisor take:

Rechallenge chemotherapty is not superior to other chemotherapies for patients with sensitive-relapse small cell lung cancer (SCLC), according to a Japanese study published in the American Journal of Clinical Oncology. Therefore, monotherapy such as amrubicin may be a reasonable form of second-line chemotherapy.

Researchers led by Kazushige Wakuda, PhD, from the Shizuoka Cancer Center Hospital in Japan looked at 65 patients who were assessable for efficacy and safety evaluation in order to evaluate the effect of rechallenge chemotherapy compared to those treated with other regimens in sensitive-relapse SCLC.

Endpoints were overall survival (OS), progression-free survival (PFS), and toxicity. Sensitive-relapse was defined as treatment-free intervals of 90 days or more.

They found no significant difference in OS between the rechallenge group (14.4 months) and those that were treated with other regimens (13.1 months), including amrubicin.

The researchers also found no difference in response to first-line treatment, although treatment-free intervals were significantly longer in the rechallenge group.

Prophylactic Cranial Irradiation Doesn't Prolong OS in Extensive Disease-SCLC
Rechallenge chemotherapty is not superior to other chemotherapies for patients with sensitive-relapse SCLC.
Objective of this study is to evaluate the efficacy of rechallenge with current induction regimens for sensitive-relapse small cell lung cancer (SCLC) patients. Rechallenge chemotherapy did not prove superior to other chemotherapies, suggesting that monotherapy, such as amrubicin, might be reasonable as second-line chemotherapy for sensitive-relapse SCLC patients.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs